Artículos por temáticas

Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease

Grossberg G, Meng X, Olin JT.

Am J Alzheimers Dis Other Demen. 2011 Feb;26(1):65-71. doi: 10.1177/1533317510391240.

Sertraline for the treatment of depression in Alzheimer disease: genetic influences

Peters ME, Vaidya V, Drye LT, Rosenberg PB, Martin BK, Porsteinsson AP, Frangakis CE, Mintzer J, Weintraub D, Schneider LS, Rabins PV, Munro CA, Meinert CL, Lyketsos CG, Avramopoulos D; DIADS-2 Resear

J Geriatr Psychiatry Neurol. 2011 Dec;24(4):222-8. doi: 10.1177/0891988711422527.

Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases

Kawamata J, Shimohama S.

J Alzheimers Dis. 2011;24 Suppl 2:95-109. doi: 10.3233/JAD-2011-110173.

The use of chronobiotics in the resynchronization of the sleep/wake cycle. Therapeutical application in the early phases of Alzheimer's disease

Cardinali DP, Furio AM, Brusco LI.

Recent Pat Endocr Metab Immune Drug Discov. 2011 May;5(2):80-90. doi: 10.2174/187221411799015354.

Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets

Lee VM, Brunden KR, Hutton M, Trojanowski JQ.

Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006437. doi: 10.1101/cshperspect.a006437.

Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease?

Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA.

Ageing Res Rev. 2011 Apr;10(2):264-73. doi: 10.1016/j.arr.2011.01.001. Epub 2011 Jan 22.

Transdermal rivastigmine: management of cutaneous adverse events and review of the literature

Greenspoon J, Herrmann N, Adam DN.

CNS Drugs. 2011 Jul;25(7):575-83. doi: 10.2165/11592230-000000000-00000.

Role of metal dyshomeostasis in Alzheimer's disease

Bonda DJ, Lee HG, Blair JA, Zhu X, Perry G, Smith MA.

Metallomics. 2011 Mar;3(3):267-70. doi: 10.1039/c0mt00074d. Epub 2011 Feb 7.

The assessment and management of pain in the demented and non-demented elderly patient

Andrade DC, Faria JW, Caramelli P, Alvarenga L, Galhardoni R, Siqueira SR, Yeng LT, Teixeira MJ.

Arq Neuropsiquiatr. 2011;69(2B):387-94. doi: 10.1590/s0004-282x2011000300023.

Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine

Flood DG, Marek GJ, Williams M.

Biochem Pharmacol. 2011 Jun 15;81(12):1422-34. doi: 10.1016/j.bcp.2011.01.021. Epub 2011 Feb 3.

[Support for patients with Alzheimer's disease and their caregivers by gerontechnology]

Rigaud AS, Pino M, Wu YH, DE Rotrou J, Boulay M, Seux ML, Hugonot-Diener L, DE Sant'anna M, Moulin F, LE Gouverneur G, Cristancho-Lacroix V, Lenoir H.

Geriatr Psychol Neuropsychiatr Vieil. 2011 Mar;9(1):91-100. doi: 10.1684/pnv.2010.0248.

Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues

Brambilla D, Le Droumaguet B, Nicolas J, Hashemi SH, Wu LP, Moghimi SM, Couvreur P, Andrieux K.

Nanomedicine. 2011 Oct;7(5):521-40. doi: 10.1016/j.nano.2011.03.008. Epub 2011 Apr 6.

Use of memantine for the treatment of dementia

Lo D, Grossberg GT.

Expert Rev Neurother. 2011 Oct;11(10):1359-70. doi: 10.1586/ern.11.132.

Solanezumab for Alzheimer's disease

Samadi H, Sultzer D.

Expert Opin Biol Ther. 2011 Jun;11(6):787-98. doi: 10.1517/14712598.2011.578573. Epub 2011 Apr 20.

[Gamma-secretase inhibitors and modulators]

Iwai A.

Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:83-7.